{"id":343,"date":"2024-11-08T09:50:11","date_gmt":"2024-11-08T09:50:11","guid":{"rendered":"https:\/\/admit:8890\/news\/"},"modified":"2025-05-10T10:27:04","modified_gmt":"2025-05-10T10:27:04","slug":"news","status":"publish","type":"page","link":"https:\/\/admit-therapeutics.com\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">News<\/h1>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-query is-layout-flow wp-block-query-is-layout-flow\">\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\"><ul class=\"columns-3 wp-block-post-template is-layout-grid wp-container-core-post-template-is-layout-2f3213d7 wp-block-post-template-is-layout-grid\"><li class=\"wp-block-post post-1410 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market\/\" target=\"_self\" >ADmit Therapeutics Obtains CLIA Certification, Opening Doors to the U.S. Healthcare Market<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), December\u00a04, 2025. ADmit Therapeutics today announced that it has obtained the\u00a0CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare &amp; Medicaid Services (CMS), confirms compliance with the most\u00a0stringent standards for analytical quality and reliability. Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1388 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction\/\" target=\"_self\" >ADmit Therapeutics Presents Innovation in Seville: The MAP-AD\u00ae\u00a0Test and New Data on Alzheimer&#8217;s Prediction<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">The company will attend the SEN Annual Meeting with its MAP-AD\u00ae&nbsp;test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer&#8217;s disease dementia prognosis. Barcelona (Spain), November 14, 2025\u00a0\u2013 ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming\u00a0Annual Meeting of the Spanish Society of Neurology<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1364 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-to-showcase-european-innovation-at-medica-2025\/\" target=\"_self\" >ADmit Therapeutics to showcase European innovation at MEDICA 2025<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), November 13,2025. We are proud to announce that our company has been selected to participate in MEDICA 2025, taking place from 17\u201320 November 2025 in D\u00fcsseldorf, Germany. ADmit Therapeutis will be at the EIC Pavilion at Messe D\u00fcsseldorf \u2013 Hall 15, Booth 15B41. Our company is one of the 15 SMEs, start-ups, and<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-to-showcase-european-innovation-at-medica-2025\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1345 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-was-named-best-startup-2025-at-the-wa4steam-awards\/\" target=\"_self\" >ADmit Therapeutics was named Best Startup 2025 at the WA4STEAM Awards<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, October 21, 2025 &#8211; ADmit Therapeutics was named Best Startup 2025 at the WA4STEAM Awards celebrated in Madrid last Friday, October 17th. This is the second edition of the WA4STEAM Awards, which recognizes, promotes, and gives greater visibility to women leaders in the entrepreneurial ecosystem (founders, startups, and ecosystem members) who are becoming true<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-was-named-best-startup-2025-at-the-wa4steam-awards\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1321 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/the-map-ad-test-obtains-the-ce-ivdr-mark-the-first-prognostic-test-for-alzheimers-disease-dementia\/\" target=\"_self\" >The MAP-AD\u00ae\u00a0Test obtains the CE-IVDR mark, the first prognostic test for Alzheimer\u2019s disease dementia<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain,) September 19, 2025. ADmit Therapeutics S.L. announced today that its disruptive blood test for the prognosis of Alzheimer&#8217;s dementia, the\u00a0MAP-AD\u00ae Test, has received the\u00a0CE Mark under the In Vitro Diagnostic Regulation (IVDR, 2017\/746). This certification confirms that the test complies with the European Union&#8217;s strict safety and performance standards, a significant milestone for<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/the-map-ad-test-obtains-the-ce-ivdr-mark-the-first-prognostic-test-for-alzheimers-disease-dementia\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1319 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem;\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-publishes-a-key-study-on-a-new-blood-based-biomarker-that-predicts-the-progression-to-alzheimers-dementia\/\" target=\"_self\" >ADmit Therapeutics publishes a key study on a new blood-based biomarker that predicts the progression to Alzheimer\u2019s dementia<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, September 19, 2025\u2013 ADmit Therapeutics S.L. today announced the publication of a blood biomarker in the journal\u00a0iScience\u00a0(Cell Press).\u00a0The study details the fundamental research that led to the development of the\u00a0Test MAP-AD\u00ae, a prognostic solution based on\u00a0mitochondrial DNA methylation levels in blood\u00a0that predicts progression to Alzheimer&#8217;s dementia in patients with Mild Cognitive Impairment (MCI). The<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-publishes-a-key-study-on-a-new-blood-based-biomarker-that-predicts-the-progression-to-alzheimers-dementia\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><\/ul><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>News<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-343","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=343"}],"version-history":[{"count":6,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343\/revisions"}],"predecessor-version":[{"id":1014,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343\/revisions\/1014"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}